HOME >> MEDICINE >> NEWS
Postmenopausal hormone therapy appears to increase risk of blood clots in veins

Estrogen therapy may increase the risk of venous thrombosis, the formation of blood clots in the veins, among postmenopausal women who have had their uterus removed, according to a study in the April 10 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

Venous thromboembolism (VT), which includes the conditions deep vein thrombosis (a blood clot in a deep vein) and pulmonary embolism (a blood clot that travels to the lungs), affects about one adult per 1,000 years of life, according to background information in the article. Researchers suspect that hormone therapy may increase a woman's risk of developing VT. The largest study analyzing the relationship between hormone therapy and VT is the Women's Health Initiative (WHI), which included two large clinical trials. One WHI trial examined the effects of estrogen plus progestin and found that this combination of hormones appeared to increase the risk of VT.

J. David Curb, M.D., University of Hawaii and Pacific Health Research Institute, Honolulu, and colleagues analyzed data from the other WHI trial, in which the effect of estrogen alone was studied in 10,739 women aged 50 to 79 years. The participants were randomly assigned to take either combined equine estrogens (a mix of several estrogens) or placebo. They were followed for an average of 7.1 years, during which 197 women developed VT, including 144 with deep vein thrombosis, 91 with pulmonary embolism and 38 with both.

Of those 197 women who developed VT, 111 were taking estrogen and 86 were taking placebo. The risk of VT was slightly higher for women receiving estrogen therapy; was significantly increased for deep venous thrombosis, but not significantly increased for pulmonary embolism; and was highest in the first two years of therapy. Estrogen therapy appeared to affect risk more in women with higher physical activity levels and lower HDL (good) cholesterol. Overall, the risk of venous thrombosis associat
'"/>

Contact: Gregg Takayama
808-692-0988
JAMA and Archives Journals
10-Apr-2006


Page: 1 2

Related medicine news :

1. Postmenopausal women with heart disease should take aspirin
2. Low-carb diets effects linked to rise in newly identified starvation hormone
3. COX inhibitors may weaken protective qualities of estrogen hormone therapy
4. UW study to clarify safety, effectiveness of hormone therapy during menopause
5. Alternative hormone treatment could help fight against breast cancer
6. Reducing cardiovascular disease risk factors when discontinuing hormone replacement therapy
7. Your brain and hormones may conspire to make you fat
8. Sex and prenatal hormone exposure affect cognitive performance, Yerkes scientists find
9. First step in developing heart hormone-based pill to control high blood pressure
10. Decline in breast cancer cases likely linked to reduced use of hormone replacement
11. Breast discomfort during hormone therapy may indicate increased risk for breast cancer

Post Your Comments:
(Date:4/23/2014)... "simple and accessible detection methods that can rapidly ... of a single cell inside that population has ... Chang Lu. , In the Royal Society of ... announced that he and his coworkers have developed ... of a protein ( Chem. Sci. , 2014, ...
(Date:4/23/2014)... are often displayed in the popular Swedish children,s ... of high-sugar foods. A new study from the ... in children,s TV programmes as well as the ... and weight status. , Steingerdur Olafsdottir,s doctoral thesis ... popular Swedish children,s TV show Bolibompa. Healthy foods ...
(Date:4/23/2014)... led by a researcher from the Cancer Science Institute ... Singapore has identified the cancer specific stem cell which ... of developing new drugs for the treatment of this ... group, led by Dr Chan Shing Leng, Research Assistant ... that a cancer-specific variant of a cell surface protein, ...
(Date:4/23/2014)... in the journal Oncotarget , explored tumour ... or their own DNA signatures within the same ... design effective, targeted treatment strategies. , Firstly they ... and either the KRAS or BRAF mutation. Secondly, ... EGFR gene mutation have that specific mutation present ...
(Date:4/23/2014)... Alzheimer,s disease has been a rapidly evolving pursuit ... latest crook in the research road, scientists have ... proteins associated with the disease. The report, which ... , could have important implications for developing novel ... colleagues explain that for years, research has suggested ...
Breaking Medicine News(10 mins):Health News:Following a protein's travel inside cells is key to improving patient monitoring, drug development 2Health News:High-calorie and low-nutrient foods in kids' TV 2Health News:Scientists identify cancer specific cell for potential treatment of gastric cancer 2Health News:Scientists identify cancer specific cell for potential treatment of gastric cancer 3Health News:Non-uniform genetic mutations identified in lung cancers could lead to targeted treatment 2
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com announces ... available in its catalogue: ... Forecast and Market Analysis to 2022 ... Atopic Dermatitis - India Drug Forecast and ...
(Date:1/15/2014)... , Jan. 15, 2014  Zafgen, Inc., a ... needs of severely obese patients, today announced initial ... a selective inhibitor of methionine aminopeptidase 2 (MetAP2), ... form of genetic obesity.  These results showed improvements ...
(Date:1/14/2014)... InformEx, North America,s leading business partnering ... the 30 th edition of its annual conference at ... January 21-24. (Logo: http://photos.prnewswire.com/prnh/20131028/NY05330LOGO-a ) ... and specialty chemical companies will take part in the conference, ...
Breaking Medicine Technology:PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
Cached News: